Table 1.
Characteristic (n, %) | Daptomycin susceptible (n=61) | Daptomycin non-susceptible (n=16) | p value |
---|---|---|---|
Age, years (median [IQRa]) | 53 (36-64) | 48 (40-62) | 0.80Ŧ |
Male gender | 37 (61) | 12 (75) | 0.29¶ |
Cancer type | 0.73¶ | ||
AML | 37 (61) | 11 (69) | |
ALL | 14 (23) | 4 (25) | |
Other leukemia | 10 (16) | 1 (6) | |
Active chemotherapy | 58 (95) | 16 (100) | 0.37¶ |
Salvage chemotherapy | 46 (79) | 13 (81) | 0.86¶ |
ANC < 500 (cells / mm3) | 49 (80) | 15 (94) | 0.20¶ |
Number of hospital days in previous 90 days (median [IQRa]) | 37 (17-52) | 36 (22-67) | 0.61Ŧ |
History of stem cell transplant | 22 (36) | 4 (25) | 0.41¶ |
Positive VREb stool screen within 90 days prior to bacteremia | 38 (62) | 9 (56) | 0.66¶ |
Select antibiotic use within 90 days prior to bacteremia | |||
Vancomycin | 21 (34) | 4 (25) | 0.47¶ |
Linezolid | 57 (93) | 16 (100) | 0.29¶ |
Levofloxacin | 42 (69) | 13 (81) | 0.33¶ |
Cefepime | 55 (90) | 12 (75) | 0.11¶ |
Piperacillin/ tazobactam | 40 (66) | 13 (81) | 0.23¶ |
Meropenem | 48 (79) | 15 (94) | 0.16¶ |
Daptomycin usage | |||
Number of daptomycin days in previous 90 days (median [IQRa]) | 0.0 (0.0-7.0) | 13.0 (4.5-16.0) | <0.01Ŧ |
Any daptomycin use within 14 days of isolate | 15 (25) | 7 (44) | 0.13¶ |
Any daptomycin use within 30 days of isolate | 19 (31) | 10 (63) | 0.02¶ |
Any daptomycin use within 90 days of isolate | 27 (44) | 14 (88) | 0.01¶ |
≥ 13 days of daptomycin use within 90 days of isolate | 7 (11) | 9 (60) | 0.01¶∫ |
Interquartile range
Vancomycin-resistant Enterococcus faecium
Wilcoxon rank-sum test
χ2 test
Relative risk 5.31 (95% CI 2.36–11.96, p <0.01)